CTOs on the Move

Quench Bio

www.quenchbio.com

 
Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.quenchbio.com
  • 400 Technology Square 10th Floor
    Cambridge, MA USA 02139
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Quench Bio raised $50M on 01/27/2020

Similar Companies

Minute Molecular Diagnostics

Minute Molecular Diagnostics was founded in 2017 as a spinout of the Northwestern University Center for Innovation in Global Health Technology (CIGHT). Comprised of a strong management team with extensive diagnostic industry experience, the company has raised $8 million in funding from the NIH and Diagnostic Industry Executives.

NICO

NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.

Potenza Therapeutics

Potenza Therapeutics is a biotechnology company focused on building a diverse portfolio of oncology programs that utilize the body`s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms. Our programs are built upon novel biological insights into the tumor microenvironment and mechanisms by which cancer cells evade detection and destruction by the immune system. Potenza Therapeutics was founded in 2014 and is located in Cambridge, MA.

Advanced BioHealing

Advanced BioHealing is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Muse bio

Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.